Company intelligence / Profile preview

TaiMed Biologics

Neihu District, Taipei City, Taiwantaimedbiologics.com ↗

Ownership: Public · 4147
Employees: ~81
Development stage: Commercial

Overview

Commercializing Trogarzo® (ibalizumab) for multi-drug resistant HIV while advancing long-acting mAb combinations and exploring ADCs through strategic investments. Recent Phase IIa success with TMB-365/380 combination therapy.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Monoclonal antibodies(Antibody-Drug Conjugates via Marigold Therapeutics investment)
Industry: Biotech

Drug pipeline

6 assets

ibalizumab

Approved

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on TaiMed Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TaiMed Biologics.

Explore the full profile